Bicara Therapeutics (BCAX) Competitors $13.35 +0.34 (+2.61%) Closing price 04:00 PM EasternExtended Trading$13.42 +0.07 (+0.52%) As of 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends BCAX vs. SRRK, AKRO, MRUS, ALVO, APLS, CRNX, VKTX, RYTM, ACAD, and MORShould you be buying Bicara Therapeutics stock or one of its competitors? The main competitors of Bicara Therapeutics include Scholar Rock (SRRK), Akero Therapeutics (AKRO), Merus (MRUS), Alvotech (ALVO), Apellis Pharmaceuticals (APLS), Crinetics Pharmaceuticals (CRNX), Viking Therapeutics (VKTX), Rhythm Pharmaceuticals (RYTM), ACADIA Pharmaceuticals (ACAD), and MorphoSys (MOR). These companies are all part of the "pharmaceutical products" industry. Bicara Therapeutics vs. Scholar Rock Akero Therapeutics Merus Alvotech Apellis Pharmaceuticals Crinetics Pharmaceuticals Viking Therapeutics Rhythm Pharmaceuticals ACADIA Pharmaceuticals MorphoSys Bicara Therapeutics (NASDAQ:BCAX) and Scholar Rock (NASDAQ:SRRK) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, community ranking, institutional ownership, valuation, profitability, analyst recommendations, earnings, media sentiment and risk. Do analysts rate BCAX or SRRK? Bicara Therapeutics presently has a consensus target price of $36.50, suggesting a potential upside of 182.74%. Scholar Rock has a consensus target price of $40.43, suggesting a potential upside of 16.93%. Given Bicara Therapeutics' higher possible upside, equities research analysts plainly believe Bicara Therapeutics is more favorable than Scholar Rock.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bicara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Scholar Rock 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 Does the media refer more to BCAX or SRRK? In the previous week, Bicara Therapeutics and Bicara Therapeutics both had 7 articles in the media. Scholar Rock's average media sentiment score of 1.15 beat Bicara Therapeutics' score of 0.83 indicating that Scholar Rock is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bicara Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Scholar Rock 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals have more ownership in BCAX or SRRK? 91.1% of Scholar Rock shares are held by institutional investors. 19.2% of Scholar Rock shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has preferable valuation and earnings, BCAX or SRRK? Bicara Therapeutics has higher earnings, but lower revenue than Scholar Rock. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBicara TherapeuticsN/AN/AN/AN/AN/AScholar Rock$33.19M98.63-$165.79M-$2.45-14.11 Does the MarketBeat Community prefer BCAX or SRRK? Scholar Rock received 155 more outperform votes than Bicara Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Bicara Therapeutics an outperform vote while only 66.01% of users gave Scholar Rock an outperform vote. CompanyUnderperformOutperformBicara TherapeuticsOutperform Votes12100.00% Underperform VotesNo VotesScholar RockOutperform Votes16766.01% Underperform Votes8633.99% Is BCAX or SRRK more profitable? Bicara Therapeutics' return on equity of 0.00% beat Scholar Rock's return on equity.Company Net Margins Return on Equity Return on Assets Bicara TherapeuticsN/A N/A N/A Scholar Rock N/A -145.60%-91.83% SummaryScholar Rock beats Bicara Therapeutics on 6 of the 11 factors compared between the two stocks. Remove Ads Get Bicara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCAX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCAX vs. The Competition Export to ExcelMetricBicara TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$702.57M$6.94B$5.64B$7.95BDividend YieldN/A2.72%4.89%4.05%P/E RatioN/A6.0823.6718.79Price / SalesN/A223.60372.21119.12Price / CashN/A65.6738.0534.64Price / BookN/A6.656.884.21Net IncomeN/A$139.78M$3.19B$247.07M7 Day Performance-18.03%-2.04%5.66%-2.44%1 Month Performance-1.60%-8.65%-0.78%-10.43%1 Year PerformanceN/A-4.69%12.75%0.94% Bicara Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCAXBicara TherapeuticsN/A$13.35+2.6%$36.50+173.4%N/A$726.45MN/A0.0032Analyst ForecastLockup ExpirationNews CoverageSRRKScholar Rock3.6788 of 5 stars$35.15-2.4%$40.43+15.0%+115.5%$3.33B$33.19M-14.96140Insider TradeAKROAkero Therapeutics4.0815 of 5 stars$41.68-1.0%$76.29+83.0%+61.1%$3.32BN/A-11.1130Insider TradeMRUSMerus2.3089 of 5 stars$46.75+1.5%$85.31+82.5%+7.0%$3.23B$36.13M-11.8437Analyst ForecastALVOAlvotech2.1474 of 5 stars$10.70-4.0%$18.00+68.2%-25.8%$3.23B$391.87M-5.781,026Short Interest ↑APLSApellis Pharmaceuticals4.2202 of 5 stars$25.14+0.4%$45.53+81.1%-57.0%$3.16B$781.37M-12.38770Short Interest ↑CRNXCrinetics Pharmaceuticals4.1868 of 5 stars$33.75+1.4%$72.64+115.2%-13.1%$3.14B$1.04M-9.05210Positive NewsVKTXViking Therapeutics4.3933 of 5 stars$27.96-3.9%$96.31+244.4%-56.0%$3.14BN/A-27.9620Analyst ForecastNews CoverageRYTMRhythm Pharmaceuticals4.2966 of 5 stars$48.56-4.4%$69.31+42.7%+27.7%$3.07B$130.13M-11.21140ACADACADIA Pharmaceuticals4.4695 of 5 stars$17.19-2.1%$24.00+39.6%-16.1%$2.87B$957.80M22.04510MORMorphoSysN/A$18.96flat$18.25-3.7%N/A$2.86B$238.28M-5.45730 Remove Ads Related Companies and Tools Related Companies SRRK Competitors AKRO Competitors MRUS Competitors ALVO Competitors APLS Competitors CRNX Competitors VKTX Competitors RYTM Competitors ACAD Competitors MOR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCAX) was last updated on 3/13/2025 by MarketBeat.com Staff From Our Partners$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicara Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bicara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
